

Health Technology Assessment Policy and Methods Review

Research and analysis plan: evidence to inform the HTA Review



In addition to feedback from stakeholders collected through consultations, the HTA Policy and Methods Review will be informed by papers analysing policy and methods used by the Pharmaceutical Benefits Advisory Committee, contemporary research, relevant methodologies and purchasing practices used by comparable international jurisdictions.

These papers will be prepared by the Department of Health and Aged Care and HTA experts. They will consider approaches to HTA in Australia and internationally in depth, from early identification of emerging technologies to ongoing assessment of health technologies after they are subsidised covering the health technologies, policies, methods, funding and approval pathways identified in the terms of reference.

Papers (and relevant lead)	Terms of Reference: Health technologies	Terms of Reference: Policies and methods	Terms of Reference: Funding and approval
Consumer engagement and consideration in HTA (Department of Health and Aged Care)	all medicines and vaccines	identification of place of a technology in care and selection of comparators	approaches that incentivise launch of first in class technologies or first major extension of indication
Emerging health technologies (Department of Health and Aged Care)	highly specialised therapies (such as cell and gene therapies)	identification of patient relevant outcomes; augmentation of primary clinical evidence with data designed to capture the value of health technologies from the perspective of patients and their communities; incorporation and use of direct input from patients, clinicians and other stakeholders with professional or lived expertise, into HTA evaluations and deliberations	equitable distribution and efficient use of limited HTA resources
Australian market approval, funding and assessment pathways and timelines and special pathways and equity considerations (Department of Health and Aged Care)	other health technologies that improve health outcomes associated with the technologies above	evaluations (including how the value of medicines is captured)	implications of any recommendations for assessment of other health technologies and hospital funding
International health technology market approval, funding and assessment pathways (Adelaide Health Technology Assessment)	foreseeable changes in health care that may influence, the need, accessibility, effectiveness or cost-effectiveness of new health technologies	approaches to increasing transparency in HTA decision-making and communication	management of future advances in health care
Early identification of emerging technologies and early value assessment (Adelaide Health Technology Assessment)		new technologies, or expanded indications, that provide a substantial improvement in health outcomes compared to relevant alternative therapies and those that do not	consideration of equity of access in HTA decision making
HTA Methods: Determination of Population Intervention Comparator Outcome (PICO) (Adelaide Health Technology Assessment)		managing clinical, economic, financial, and other uncertainty throughout the lifecycle of a technology	the feasibility of international work sharing for evaluation of technologies in scope for the HTA Review
HTA Methods: Clinical Evaluation (Adelaide Health Technology Assessment)		assessment of technologies (such as those for rare and ultra-rare diseases) that would be used for conditions where there is high unmet clinical need that have clinical and economic uncertainty	purchasing practices used by comparable international jurisdictions.
HTA Methods: Economic Evaluation (Centre for Health Economics Research and Evaluation)			
Funding and purchasing decisions and Managing Uncertainty (Centre for Health Economics Research and Evaluation)			
Options for optimising the availability and use of real world data and production of real world evidence to support HTA decision-making throughout the lifecycle of health technologies (Centre of Research Excellence in Medicines Intelligence)			

**Note: Dates are indicative only. More information including exact dates will be released as the Review progresses.*

